PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Nicholas J Vogelzang Selected Research
Hormones
02/2008
Second-line Chemotherapy for Advanced Hormone-refractory Prostate Cancer.
07/2007
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
07/2006
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
03/2006
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
03/2006
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
08/2005
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
05/2005
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
04/2005
Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
03/2005
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
11/2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
08/2004
Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
05/2004
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
02/2004
Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.
01/2004
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
12/2003
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
04/2003
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
02/2003
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
04/2002
Importance of serum hemoglobin in hormone refractory prostate cancer.
02/2002
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
Articles by Research Topic
Disease
26
Prostatic Neoplasms (Prostate Cancer)
05/2008 - 04/2002
24
Neoplasms (Cancer)
04/2008 - 01/2002
13
Leukemia
04/2008 - 02/2002
8
Mesothelioma
05/2008 - 01/2002
7
Carcinoma (Carcinomatosis)
01/2007 - 02/2002
6
Renal Cell Carcinoma (Grawitz Tumor)
02/2007 - 05/2002
3
Kidney Neoplasms (Kidney Cancer)
07/2008 - 06/2003
2
Urinary Bladder Neoplasms (Bladder Cancer)
09/2006 - 08/2003
1
Pain (Aches)
05/2008
1
Anoxia (Hypoxia)
03/2008
1
Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
01/2007
1
Neoplasm Metastasis (Metastasis)
03/2006
1
Venous Thromboembolism
10/2002
1
Urogenital Neoplasms
02/2002
Drug/Important Bio-Agent (IBA)
19
Hormones
IBA
02/2008 - 02/2002
9
gemcitabine
FDA Link
09/2006 - 01/2002
5
Fluorouracil (Carac)
FDA Link
Generic
01/2007 - 05/2002
4
Cisplatin (Platino)
FDA Link
Generic
09/2006 - 07/2003
4
Suramin (Suramin Sodium)
IBA
11/2004 - 07/2002
3
Ketoconazole (Nizoral)
FDA Link
Generic
11/2007 - 03/2004
3
Interleukin-2 (IL2)
IBA
03/2006 - 05/2002
3
docetaxel (Taxotere)
FDA Link
05/2005 - 12/2003
2
Leucovorin (Folinic Acid)
FDA Link
Generic
01/2007 - 03/2006
2
ranpirnase (Pannon)
IBA
04/2006 - 01/2002
2
flt3 ligand protein (flt3 ligand)
IBA
02/2004 - 05/2002
2
pemetrexed (MTA)
FDA Link
07/2003 - 06/2003
2
atrasentan
IBA
03/2003 - 02/2003
1
Protein-Tyrosine Kinases (Tyrosine Kinase)
IBA
07/2008
1
5,6-dihydro-5-azacytidine
IBA
04/2008
1
glucuronyl glucosamine glycan sulfate (Vessel)
IBA
03/2008
1
Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
IBA
03/2008
1
Etoposide (VP 16)
FDA Link
Generic
11/2007
1
zoledronic acid (zoledronate)
FDA Link
07/2007
1
sunitinib (Sutent)
FDA Link
02/2007
1
TP protocol
IBA
01/2007
1
Ribonucleases (Ribonuclease)
IBA
04/2006
1
N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl- 2,5- dioxo- 1- imidazolidinyl)butyl)- L- leucyl- N,3- dimethyl-L-Valinamide
IBA
03/2006
1
Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
IBA
03/2006
1
nilutamide (Nilandron)
FDA Link
10/2005
1
Flutamide (Eulexin)
FDA Link
Generic
10/2005
1
bicalutamide (Casodex)
FDA Link
10/2005
1
Chromogranin A
IBA
08/2005
1
sulindac sulfone (exisulind)
IBA
05/2005
1
Methotrexate (Mexate)
FDA Link
Generic
04/2005
1
Interleukin-6 (Interleukin 6)
IBA
03/2005
1
tyrosine receptor (receptor, tyrosine)
IBA
11/2004
1
CEP 2563
IBA
11/2004
1
Phosphotransferases (Kinase)
IBA
11/2004
1
Epidermal Growth Factor Receptor (EGF Receptor)
IBA
08/2004
1
Epidermal Growth Factor (EGF)
IBA
08/2004
1
SU 5416 (SU5416)
IBA
05/2004
1
Estradiol (Estrace)
FDA Link
Generic
01/2004
1
alpha-methylacyl-CoA racemase
IBA
01/2004
1
bortezomib (Velcade)
FDA Link
01/2004
1
Estramustine
FDA Link
12/2003
1
Granulocyte Colony-Stimulating Factor (G-CSF)
IBA
12/2003
1
Carboplatin (JM8)
FDA Link
Generic
12/2003
1
Androgen Receptors (Androgen Receptor)
IBA
07/2003
1
oxaliplatin (Eloxatin)
FDA Link
07/2003
1
Paclitaxel (Taxol)
FDA Link
Generic
06/2003
1
Endothelin Receptors (Endothelin Receptor)
IBA
03/2003
1
Endothelin A Receptor
IBA
02/2003
1
Thalidomide (Thalomid)
FDA Link
10/2002
1
Interferon-alpha (Interferon Alfa)
FDA Link
05/2002
1
Hemoglobins (Hemoglobin)
IBA
04/2002
1
Folic Acid Antagonists
IBA
02/2002
1
Mitoxantrone (Novantrone)
FDA Link
Generic
02/2002
1
capecitabine (Xeloda)
FDA Link
01/2002
Therapy/Procedure
8
Drug Therapy (Chemotherapy)
05/2008 - 04/2002
4
Castration
05/2008 - 11/2005
2
Stem Cell Transplantation
01/2003 - 04/2002
1
Prostatectomy (Retropubic Prostatectomy)
02/2007
1
Immunotherapy
02/2004
1
Nephrectomy
02/2004
1
Cystectomy
08/2003